Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®)

Review of development and future perspectives

Yoshihiko Maehara, Shunichi Tsujitani, Hiroshi Saeki, Eiji Oki, Keiji Yoshinaga, Yasunori Emi, Masaru Morita, Shunji Kohnoe, Yoshihiro Kakeji, Tokujiro Yano, Hideo Baba

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.

Original languageEnglish
Pages (from-to)8-28
Number of pages21
JournalSurgery today
Volume42
Issue number1
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Proteins
Drug Therapy
Neoplasms
Interleukin-15
Induction Chemotherapy
Small Cell Lung Carcinoma
Transforming Growth Factors
Adjuvant Chemotherapy
krestin
Immunosuppression
Dendritic Cells
Stomach Neoplasms
Meta-Analysis
Monocytes
Colorectal Neoplasms
Biomarkers
Quality of Life
Apoptosis
Neoplasm Metastasis
Survival

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®) : Review of development and future perspectives. / Maehara, Yoshihiko; Tsujitani, Shunichi; Saeki, Hiroshi; Oki, Eiji; Yoshinaga, Keiji; Emi, Yasunori; Morita, Masaru; Kohnoe, Shunji; Kakeji, Yoshihiro; Yano, Tokujiro; Baba, Hideo.

In: Surgery today, Vol. 42, No. 1, 01.01.2012, p. 8-28.

Research output: Contribution to journalReview article

Maehara, Y, Tsujitani, S, Saeki, H, Oki, E, Yoshinaga, K, Emi, Y, Morita, M, Kohnoe, S, Kakeji, Y, Yano, T & Baba, H 2012, 'Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®): Review of development and future perspectives', Surgery today, vol. 42, no. 1, pp. 8-28. https://doi.org/10.1007/s00595-011-0075-7
Maehara, Yoshihiko ; Tsujitani, Shunichi ; Saeki, Hiroshi ; Oki, Eiji ; Yoshinaga, Keiji ; Emi, Yasunori ; Morita, Masaru ; Kohnoe, Shunji ; Kakeji, Yoshihiro ; Yano, Tokujiro ; Baba, Hideo. / Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®) : Review of development and future perspectives. In: Surgery today. 2012 ; Vol. 42, No. 1. pp. 8-28.
@article{dd6cf1031554479b8d49131022502828,
title = "Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN{\circledR}): Review of development and future perspectives",
abstract = "The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN{\circledR}) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.",
author = "Yoshihiko Maehara and Shunichi Tsujitani and Hiroshi Saeki and Eiji Oki and Keiji Yoshinaga and Yasunori Emi and Masaru Morita and Shunji Kohnoe and Yoshihiro Kakeji and Tokujiro Yano and Hideo Baba",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s00595-011-0075-7",
language = "English",
volume = "42",
pages = "8--28",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN®)

T2 - Review of development and future perspectives

AU - Maehara, Yoshihiko

AU - Tsujitani, Shunichi

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Yoshinaga, Keiji

AU - Emi, Yasunori

AU - Morita, Masaru

AU - Kohnoe, Shunji

AU - Kakeji, Yoshihiro

AU - Yano, Tokujiro

AU - Baba, Hideo

PY - 2012/1/1

Y1 - 2012/1/1

N2 - The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.

AB - The mechanism of action of protein-bound polysaccharide K (PSK; KRESTIN®) involves the following actions: (1) recovery from immunosuppression induced by humoral factors such as transforming growth factor (TGF)-β or as a result of surgery and chemotherapy; (2) activation of antitumor immune responses including maturation of dendritic cells, correction of Th1/Th2 imbalance, and promotion of interleukin-15 production by monocytes; and (3) enhancement of the antitumor effect of chemotherapy by induction of apoptosis and inhibition of metastasis through direct actions on tumor cells. The clinical effectiveness of PSK has been demonstrated for various cancers. In patients with gastric or colorectal cancer, combined use of PSK with postoperative adjuvant chemotherapy prolongs survival, and this effect has been confirmed in multiple meta-analyses. For small-cell lung carcinoma, PSK in conjunction with chemotherapy prolongs the remission period. In addition, PSK has been shown to be effective against various other cancers, reduce the adverse effects of chemotherapy, and improve quality of life. Future studies should examine the effects of PSK under different host immune conditions and tumor properties, elucidate the mechanism of action exhibited in each situation, and identify biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84857795063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857795063&partnerID=8YFLogxK

U2 - 10.1007/s00595-011-0075-7

DO - 10.1007/s00595-011-0075-7

M3 - Review article

VL - 42

SP - 8

EP - 28

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 1

ER -